Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
2 September 2024 |
Main ID: |
NCT04924114 |
Date of registration:
|
26/02/2021 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Study of MK-6194 (PT101) in Participants With Active Ulcerative Colitis (UC) (MK-6194-002)
|
Scientific title:
|
A Phase 1b, Randomized, Adaptive, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of PT101 in Subjects With Active Ulcerative Colitis |
Date of first enrolment:
|
October 14, 2021 |
Target sample size:
|
57 |
Recruitment status: |
Completed |
URL:
|
https://clinicaltrials.gov/ct2/show/NCT04924114 |
Study type:
|
Interventional |
Study design:
|
Allocation: Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
|
Phase:
|
Phase 1
|
|
Countries of recruitment
|
Georgia
|
Germany
|
Hungary
|
Moldova, Republic of
|
Poland
|
Ukraine
|
United Kingdom
|
United States
|
Contacts
|
Name:
|
Medical Director |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
Merck Sharp & Dohme LLC |
| | |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- Diagnosis of UC at least 3 months prior to screening.
- Mildly to severely active UC.
- Inadequate response, loss of response, or intolerance to at least 1 prior
conventional therapy, and no more than 2 prior advanced therapies.
- Participants at risk for colorectal cancer must have a colonoscopy prior to or at
screening as follows:
- Participants > 50 years of age must have documentation of a colonoscopy within
3 years of the screening visit to exclude adenomatous polyps. Participants
whose adenomas have been completely excised at screening are eligible.
- Participants with extensive colitis for = 8 years, or disease limited to the
left side of the colon for = 10 years, must either have had a full colonoscopy
to assess for the presence of dysplasia within 1 year before first
administration of study drug or a full colonoscopy to assess for the presence
of malignancy at the screening visit.
- No evidence of active tuberculosis (TB), latent TB, or inadequately treated TB.
- Women of childbearing potential (WOCBP) and males with female partners of
childbearing potential must utilize highly effective contraceptive methods beginning
4 weeks prior to first dose of study drug and continue for 30 days after the last
dose of study drug.
- Body mass index (BMI) 18 to 35 kg/m^2 inclusive and weight = 50 kg.
Exclusion Criteria:
- Prior treatment with recombinant IL-2 or modified IL-2 therapy, including MK-6194
(PT101).
- Known sensitivity to MK-6194 (PT101) or its excipients.
- Known history of hypersensitivity to interleukin-2 (IL-2).
- Disease limited to the rectum (i.e., within 15 cm of the anal verge).
- Diagnosis of toxic megacolon.
- Suspected or known colon stricture or stenosis.
- Diagnosis of Crohn's disease, or indeterminant colitis.
- Has severe colitis as evidenced by:
- Current hospitalization for the treatment of UC
- Likely to require a colectomy within 12 weeks of baseline in the opinion of the
Investigator
- At least 4 symptoms of severe colitis as identified at screening or baseline
visits.
- Previously had surgery for UC, or likely to require surgery for UC during the study
period in the opinion of the Investigator.
- History of abnormal thallium stress test or functional cardiac function test.
- History of significant cardiac, pulmonary, renal, hepatic, or central nervous system
(CNS) impairment.
- Active clinically significant infection, or any infection requiring hospitalization
or treatment with intravenous anti-infectives within 8 weeks of randomization, or
any infection requiring oral anti-infective therapy within 6 weeks of randomization.
- History of opportunistic infection.
- History of symptomatic herpes zoster within 16 weeks of randomization, or any
history of disseminated herpes simplex, disseminated herpes zoster, ophthalmic
zoster, or central nervous system (CNS) zoster.
- Currently on any chronic systemic (oral or IV) anti-infective therapy for chronic
infection (such as pneumocystis, cytomegalovirus, herpes zoster, or atypical
mycobacteria).
- Currently receiving lymphocyte depleting therapy.
- History of abnormal pulmonary function tests.
- Participants with organ or tissue allograft.
- Malignancy within 5 years of screening, with the exception of adequately treated or
excised non-metastatic basal cell or squamous cell cancer of the skin.
- Exposure to advanced therapy within 5 half-lives of the Day 1 visit, or
documentation of detectable drug during screening.
- Received a live attenuated vaccine < 1 month prior to screening or is planning to
receive a live attenuated vaccine during the study period or within 12 weeks of the
end of participation in the study.
- Is pregnant or nursing or is planning to become pregnant during the study.
- Any uncontrolled or clinically significant concurrent systemic disease other than
UC.
Age minimum:
18 Years
Age maximum:
80 Years
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
Ulcerative Colitis
|
Intervention(s)
|
Drug: MK-6194
|
Drug: MK-6194-matching placebo
|
Primary Outcome(s)
|
Percentage of Participants Discontinuing Study Treatment Due to an AE
[Time Frame: Up to approximately 85 days]
|
Percentage of Participants Experiencing Adverse Events (AEs)
[Time Frame: Up to approximately 85 days]
|
Secondary Outcome(s)
|
Change in Number of Natural Killer (NK) Cells in Whole Blood
[Time Frame: Baseline and up to 85 days (last study visit)]
|
Apparent Volume of Distribution (Vd/F) of MK-6194
[Time Frame: At designated time points (up to 85 days)]
|
Area Under the Curve From Time 0 to Infinity (AUC0-inf) of MK-6194
[Time Frame: At designated time points (up to 85 days)]
|
Maximum Concentration (Cmax) of MK-6194
[Time Frame: At designated time points (up to 85 days)]
|
Minimum Concentration (Cmin) of MK-6194
[Time Frame: At designated time points (up to 85 days)]
|
Time to Cmax (Tmax) of MK-6194
[Time Frame: At designated time points (up to 85 days)]
|
Change in Number of Peripheral Regulatory T-cells (Tregs) in Whole Blood
[Time Frame: Baseline and up to 85 days (last study visit)]
|
Area Under the Concentration Time-curve From Time 0 to the Last Quantifiable Concentration (AUC0-t)
[Time Frame: At designated time points (up to 85 days)]
|
Titer of anti-drug antibody (ADA) to MK-6194
[Time Frame: At designated time points (up to 85 days)]
|
Apparent Clearance (CL/F) of MK-6194
[Time Frame: At designated time points (up to 85 days)]
|
Apparent Half-life (t1/2) of MK-6194
[Time Frame: At designated time points (up to 85 days)]
|
Change in Number of Conventional T Cells (Tcons) in Whole Blood
[Time Frame: Baseline and up to 85 days (last study visit)]
|
Secondary ID(s)
|
2021-000093-28
|
PT101-201
|
6194-002
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|